Immune Design Announces Treatment of Patients With CMB305 Investigational Immuno-Oncology Agent

By: via Benzinga
Immune Design (Nasdaq: IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced the dosing of patients in a ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.